The role of operation for patients with recurrent diffuse low-grade glioma (DLGG) is controversial. A few studies compared the effectiveness between surgery and other treatments for those patients. We did a systematic review for the effects of reoperation for recurrent DLGG. We searched the following databases from 1990 to 2018: Medline, Cochrane Library, Scopus and Opengrey, including researches about reoperation for recurrent DLGG, regardless of comparison and study design. The Newcastle-Ottawa scale (NOS) was used for quality assessment. Ten studies with 358 participants met the criteria. Due to lack of survival data about non-operated group, we failed to analyze the effect of reoperation. The risk bias of included studies was acceptable except the comparability. However, we found 48.4 % (155/320) of patients underwent gross resection and the safety was acceptable. About 1/3 received adjuvant therapy and 41.9 % (125/298) got histologically progressed. In a word, few studies reported the survival data of recurrent DLGG patients received reoperation. Most were young adults and half of them experienced a histological progress. But there are still a lot of shortages of the existing studies and more researches on the reoperation efficacy in recurrent DLGG are needed.

中文翻译：

---

复发性弥漫性低级别胶质瘤患者手术效果：定性系统评价

手术对复发性弥漫性低级别胶质瘤 (DLGG) 患者的作用存在争议。一些研究比较了手术和其他治疗对这些患者的有效性。我们对再次手术对复发性 DLGG 的影响进行了系统评价。我们检索了 1990 年至 2018 年的以下数据库：Medline、Cochrane Library、Scopus 和 Opengrey，包括关于复发性 DLGG 再手术的研究，不考虑比较和研究设计。纽卡斯尔-渥太华量表 (NOS) 用于质量评估。有 358 名参与者的 10 项研究符合标准。由于缺乏非手术组的生存数据，我们未能分析再次手术的效果。除可比性外，纳入研究的风险偏倚是可以接受的。但是，我们发现了 48 个。4 % (155/320) 的患者接受了大体切除术，安全性是可以接受的。约 1/3 接受辅助治疗，41.9 % (125/298) 获得组织学进展。总之，很少有研究报道复发性DLGG患者接受再手术的生存数据。大多数是年轻人，其中一半经历了组织学进展。但现有研究还存在很多不足，需要对复发性DLGG的再手术疗效进行更多的研究。